Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Ovarian Carcinoma. - Finkler,N.; Gordon,A.; Crozier,M.; Edwards,R.; Figueroa,J.; Garcia,A.; Hainsworth,J.; Irwin,D.; Silberman,S.; Allen,L.; Ferrante,K.; Fisher,D.; et al. (Proc Am Soc Clin Oncol, 2001)